About Caligorrx
Caligorrx is a Healthcare company based in Secaucus (United States) founded in 2002, and was acquired by Diversis Capital in April 2016. Comparator drugs and supplies are sourced for clinical trials. Caligorrx has completed 1 acquisition, including The Coghlan Group. Its focus areas include Biopharma Outsourcing, CRO, Clinical Development and Functional Services. Its competitors include SSI Strategy and Health Decisions.
Company details
Founded in 2002 and based in Secaucus, United States, Caligorrx operates in the pharmaceutical and biotech sectors. Sourcing and supply chain solutions are provided for comparator drugs, rescue medications, combination therapies, and ancillary supplies. Logistical support is extended for worldwide clinical trials. Through Global Access Programs, regulatory solutions are facilitated to enable drug access for patients in regions lacking effective treatments or commercial availability.
- Headquarters Secaucus, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website caligorrx.com
- Social LinkedIn X
- Acquired by Diversis Capital (Apr 2016)
- Investors
- Investments & Acquisitions
- Acquired byDiversis Capital
(Apr 2016)
Investors in Caligorrx
Caligorrx has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Diversis Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in tech startups are made by Diversis Capital. | diversis.com | Los Angeles, United States |
Investor details for Caligorrx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Caligorrx
Caligorrx has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include The Coghlan Group.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Clinical trial material management and randomization services are offered. | tcgsupplies.com | Bastrop, United States | 2005 | Nov 2017 | •••• |
Complete acquisition details for Caligorrx
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Caligorrx
3 dated milestones of Caligorrx across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Caligorrx is founded.
- Exit Acquired by Diversis Capital.
- Acquisition Acquires The Coghlan Group.
Competitors of Caligorrx
Caligorrx has 2 listed competitors in our database. They include SSI Strategy and Health Decisions.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ssistrategy.com | 2010 | Parsippany Troy Hills, United States | Pharmacovigilance and medical affairs services are offered for drug development. | |||
| healthdec.com | 1989 | Durham, United States | 110 | CRO focused on clinical trial services for data management, monitoring and biostatistics |
Detailed competitors of Caligorrx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Caligorrx (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Caligorrx
Complete news archive for Caligorrx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Caligorrx
Caligorrx was founded in 2002.
Caligorrx is headquartered in Secaucus, United States. It is registered at Secaucus, New Jersey, United States.
Founded in 2002 and based in Secaucus, United States, Caligorrx operates in the pharmaceutical and biotech sectors. Sourcing and supply chain solutions are provided for comparator drugs, rescue medications, combination therapies, and ancillary supplies. Logistical support is extended for worldwide clinical trials. Through Global Access Programs, regulatory solutions are facilitated to enable drug access for patients in regions lacking effective treatments or commercial availability.
Caligorrx's top competitors include SSI Strategy and Health Decisions.
Caligorrx has made 1 acquisition, including The Coghlan Group.
Caligorrx has 1 investor. Key investors include Diversis Capital.
Yes. Caligorrx was acquired by Diversis Capital in April 2016.